Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued two new patents for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament’s latest patents were issued by the United States Patent and Trademark Office (USPTO) and describe technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.

“When Filament was founded, conventional wisdom held that producing stable psilocin was impossible. We have since been granted patent protection for successful production of psilocin at all stages of manufacture: from extraction to purification to standardization and beyond. For example, our latest issued patents around noningestive administration are demonstrable evidence of our team’s talent for innovation. The fact that we have never had a patent application denied, compared to the industry average of a less than 50% success rate, is further validation of this talent.”

Taran Grey, Director of Intellectual Property

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. On August 3, 2021, Filament was issued the first-ever patent for the extraction and standardization of natural psilocybin. Since then, the Company has been issued a total of five patents by the USPTO and five by the Canadian Intellectual Property Office.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.